LILLY AND CO news, videos and press releases
For more news please use our advanced search feature.
LILLY AND CO - More news...
LILLY AND CO - More news...
- Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels
- LillyDirect platform expands to facilitate access to Alzheimer's disease care
- Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
- Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
- Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis
- Lilly to participate in Leerink Partners Global Healthcare Conference
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor
- Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion
- Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients
- Lilly to participate in TD Cowen's 45th Annual Health Care Conference
- Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
- Lilly reports full Q4 2024 financial results and provides 2025 guidance
- Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement
- FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
- Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance
- Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
- Lilly to participate in J.P. Morgan Healthcare Conference
- FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
- Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease
- Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt
- Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease
- Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer
- Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting
- Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase
- CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® Parade
- Lilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin
- Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
- Lilly announces changes on board of directors
- Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose
- Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity
